Gil Y. Melmed MD, MS, AGAF
Co-Director, Inflammatory Bowel Disease Center; Director, Clinical Research, Inflammatory Bowel and Immunobiology Research Institute, Division of Digestive and Liver Diseases, Department of Medicine; Professor of Medicine, Cedars-Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CaliforniaGil Y. Melmed, MD, MS, is the Co-Director of the Inflammatory Bowel Disease Center and Professor of Medicine at Cedars-Sinai Medical Center in Los Angeles, California. His research and educational interests span clinical and surgical outcomes, quality of care, and preventive health issues in IBD. He has authored or coauthored more than 200 articles in peer-reviewed journals and several book chapters. He has led or participated in the development of quality indicators for IBD with the American Gastroenterology Association, the Crohn’s and Colitis Foundation, the National Quality Forum, and the Canadian Crohn’s and Colitis organizations
Disclosures
Dr. Melmed reports the following:- Consultant: AbbVie, Arena, Bristol-Myers Squibb, Boehringer-Ingelheim, Ferring, Janssen, Medtronic, Nephroceuticals, Oshi, Pfizer, Samsung Bioepis, Shield, Shionogi, Takeda
- Research funding: Pfizer